Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Scholl, Michael ^a,b   Carter, Stephen F ^a,c   Westman, Eric ^a   Rodriguez Vieitez, Elena ^a   Almkvist, Ove ^a,d   Thordardottir, Steinunn ^a   Wall, Anders ^e   Graff, Caroline ^a   Långstrom, Bengt ^e   Nordberg, Agneta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; COGNITIVE DEFECT; DOMINANT GENE; EPISODIC MEMORY; FEMALE; GENETICS; GENOTYPE; GLIOSIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PSYCHOLOGY;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITIVE DYSFUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; GENES, DOMINANT; GENOTYPE; GLIOSIS; HUMANS; MALE; MEMORY, EPISODIC; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS;

EID: 84946781137     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16404     Document Type: Article

References (62)

1. Hardy, J. A., Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
2. Nordberg, A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3, 34 (2011).
3. Chetelat, G. Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat Rev Neurol 9, 123-124 (2013).
4. Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013).
5. Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
6. Bekris, L. M., Yu, C. E., Bird, T. D., Tsuang, D. W. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23, 213-227 (2010).
7. Sch?l, M. et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 32, 1388-1399 (2011).
8. Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y., Rodriguez, J. J. Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412 (2010).
9. Heppner, F. L., Ransohoff, R. M., Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358-372 (2015).
10. Heneka, M. T., Golenbock, D. T., Latz, E. Innate immunity in Alzheimer's disease. Nat Immunol 16, 229-236 (2015).
11. McGeer, P. L., McGeer, E. G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21, 195-218 (1995).
12. McGeer, E. G., McGeer, P. L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19, 355-361 (2010).
13. Burda, J. E., Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229-248 (2014).
14. Serrano-Pozo, A. et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropath Exp Neur 72, 462-471 (2013).
15. Fowler, J. S., Logan, J., Volkow, N. D., Wang, G. J. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol 7, 377-387 (2005).
16. Tong, J. et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 33 (2013).
17. Carter, S. F. et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53, 37-46 (2012).
18. Nordberg, A. et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol I 40 (2013).
19. Eriksson, L. et al. Multi-and Megavariate Data Analysis (Part I-Basics and Principals and Applications). 2nd edn, 95-98 (Umetrics AB, 2006).
20. Forsberg, A. et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465 (2008).
21. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127 (2010).
22. Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746 (2007).
23. Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13, 614-629 (2014).
24. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011).
25. Marchesi, V. T. Alzheimer's disease 2012: the great amyloid gamble. Am J Pathol 180, 1762-1767 (2012).
26. Pimplikar, S. W. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J Clin Immunol 34 Suppl 1, S64-69 (2014).
27. Eikelenboom, P. et al. Neuroinflammation-an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 7, 38-41 (2010).
28. Steele, M. L., Robinson, S. R. Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol Aging 33, 423 e421-413 (2012).
29. Verkhratsky, A., Marutle, A., Rodriguez-Arellano, J. J., Nordberg, A. Glial Asthenia and Functional Paralysis: A New Perspective on Neurodegeneration and Alzheimer's Disease. Neuroscientist (2014).
30. Song, W., Zhou, L. J., Zheng, S. X., Zhu, X. Z. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin 21, 557-563 (2000).
31. Marutle, A. et al. 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar betaamyloid in Alzheimer brain. J Neuroinflammation 10, 90 (2013).
32. Jossan, S. S. et al. Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H] deprenyl. Brain Res 547, 69-76 (1991).
33. Kadir, A. et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 134, 301-317 (2011).
34. La Joie, R. et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci 32, 16265-16273 (2012).
35. Choo, I. H., Carter, S. F., Sch?l, M. L., Nordberg, A. Astrocytosis measured by (11)C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol I 41, 2120-2126 (2014).
36. von Bernhardi, R., Eugenin-von Bernhardi, L., Eugenin, J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 7, 124 (2015).
37. Kreisl, W. C. et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 136, 2228-2238 (2013).
38. Varrone, A. et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. Eur J Nucl Med Mol I 40, 921-931 (2013).
39. Varley, J., Brooks, D. J., Edison, P. Imaging neuroinflammation in Alzheimer's and other dementias: Recent advances and future directions. Alzheimers Dement 11, 1110-20 (2014).
40. Golla, S. S. et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients. J Cereb Blood Flow Metab 35, 766-772 (2015).
41. Owen, D. R. et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32 (2012).
42. Rousseau, A. et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropath Exp Neur 65, 1149-1156 (2006).
43. Craig-Schapiro, R. et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912 (2010).
44. Antonell, A. et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis 42, 901-908 (2014).
45. Rosen, C. et al. Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dement Geriatr Cogn Dis Extra 4, 297-304 (2014).
46. Alcolea, D. et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiol Aging 36, 2018-2023 (2015).
47. Bateman, R. J. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3, 1 (2011).
48. Lippa, C. F. et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 46, 406-412 (1996).
49. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804 (2012).
50. Benzinger, T. L. et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. P Natl Acad Sci USA 110, E4502-4509 (2013).
51. Fowler, J. S. et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18, 431-435 (1997).
52. Ryan, N. S., Fox, N. C. Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. Brain 136, e259 (2013).
53. Storandt, M., Balota, D. A., Aschenbrenner, A. J., Morris, J. C. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 28, 19-29 (2014).
54. Thordardottir, S. et al. Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. J Alzheimers Dis 43, 1393-402 (2014).
55. Sch?l, M. et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79, 229-236 (2012).
56. McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984).
57. Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194 (2004).
58. Bergman, I., Blomberg, M., Almkvist, O. The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol 48, 115-125 (2007).
59. Ashburner, J., Friston, K. J. Unified segmentation. Neuroimage 26, 839-851 (2005).
60. Hammers, A. et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19, 224-247 (2003).
61. Johansson, A. et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci 255, 17-22 (2007).
62. Pearson, K. On Lines and Planes of Closest Fit to Systems of Points in Space. Philos Mag A 2, 559-572 (1901).